Sort
82,697 grants matching “vaccine development”
Human Papillomavirus and Polyomavirus Associated Malignancies.
$897,756Denise A. Galloway · Fred Hutchinson Cancer Research Center · R35 · FY2019 · CA
PATHOGENESIS OF MUCOSAL TRANSMISSION/ACUTE SIV INFECTION
$897,733University Of Minnesota Twin Cities · R01 · FY2002 · AI
Immunologic Signatures of SARS-CoV-2 Vaccination and Disease
$897,731Dan H. Barouch · Beth Israel Deaconess Medical Center · U01 · FY2023 · CA
PIPP Phase I: Computational Foundations for Bio-social Modeling of Unseen Pandemics
$897,531Pavan K Turaga · Arizona State University · · FY2022 · ENG
CELL BIOLOGY OF MYCOBACTERIUM AVIUM INFECTION
$897,530University Of California San Francisco · P01 · FY2001 · AI
R5 SHIV/Macaque Models for the Evaluation of T and B Cell-Based HIV-1 Vaccines
$897,508Cecilia C Cheng-Mayer · Aaron Diamond Aids Research Center · R01 · FY2009 · AI
Augmenting immunity via HER2-targeted immunotherapy and PSK M.Disis/L.Standish
$897,391Leanna J Standish · Bastyr University · U19 · FY2011 · AT
PURIFICATION OF HIV ENV PROTEINS WITH AN IMMUNOAFFINITY BASED PROCESS
$897,313Antu Dey · International Aids Vaccine Initiative · N01 · FY2017 · AI
Molecular Approaches To Antiviral and Vaccine Development For Hepatitis C
$897,021T. Jake Liang · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2018 · DK
Identification of human tumor-associated antigens
$896,832Kwong Yok Tsang · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA
DEVELOPMENT OF POLY-YE AS A NEUROPROTECTIVE VACCINE AGAINST BRAIN DAMAGE RESULTING FROM ORGANOPHASPHATE INTOXICATION
$896,707Proneuron Biotechnologies (Israel), Ltd. · · FY2009 · Department of Defense
AZD9688: A First in Class Disease Modifying Therapy to Treat Alpha-1 Antitrypsin Deficiency a Genetically Linked Orphan Disease
$896,654Mark T Dransfield · University Of Alabama At Birmingham · UH3 · FY2021 · TR
Malaria Vaccine: Pfs25-rEPA
$896,624Louis Miller · National Institute Of Allergy And Infectious Diseases · ZIA · FY2009 · AI
Genome-wide sieve analysis and immunological validation to identify targets of protective efficacy in field trials of a whole-organism malaria vaccine
$896,593Joana Carneiro Da Silva · University Of Maryland Baltimore · R01 · FY2020 · AI
Overcoming pre-existing immunity to AAV to enhance AAV-based HIV immunotherapies
$896,461Mauricio De Aguiar Martins · University Of Florida · R01 · FY2023 · AI
Task B08: Development and Use of a Non-Human Primate Model of SARS-CoV-2 Infection
$896,460Fusataka Koide · Southern Research Institute · N01 · FY2020 · AI
Comprehensive antigenic mapping of the human anti-peanut IgE antibody response
$896,430Scott Alan Smith · Vanderbilt University Medical Center · R01 · FY2022 · AI
Production Development
$896,385Niranjan Y Sardesai · Wistar Institute · U19 · FY2018 · AI
Immune control of SIVagm replication in vivo
$896,377Joern E. Schmitz · Beth Israel Deaconess Medical Center · R01 · FY2009 · AI
Administrative Supplement: Interim Funding for Emory Lung Cancer SPORE
$896,274Suresh S Ramalingam · Emory University · P50 · FY2024 · CA
Modeling, Spatial, Statistics
$896,156Ira M Longini · Fred Hutchinson Cancer Research Center · U54 · FY2014 · GM
A Neonatal Monkey Model of Tuberculosis Vaccination
$896,046Chinnaswamy Jagannath · Methodist Hospital Research Institute · R01 · FY2020 · AI
Novel nanoparticulate adjuvants to enhance HIV-1 Env specific mucosal antibody responses
$895,998Sudhir Pai Kasturi · Emory University · R01 · FY2020 · AI
Tulane/LSU Pediatric AIDS Clinical Trials Unit
$895,978Tulane University Of Louisiana · U01 · FY2004 · AI
Molecular Mechanisms and Treatment Of Autoimmunity In Man And Animal Models
$895,829Michael J Lenardo · National Institute Of Allergy And Infectious Diseases · ZIA · FY2016 · AI